Trigeminal Neuralgia Represents an Attractive Orphan Opportunity in the Pain Field.
LONDON, July 21, 2015 /PRNewswire/ --
New report from Globe Life Sciences identifies trigeminal neuralgia to be an attractive orphan opportunity within the neuropathic pain market
Globe Life Sciences, a leading provider of commercial analysis within healthcare-related sectors, conducted a detailed market assessment of trigeminal neuralgia. The Globe Extraordinary report, entitled 'Trigeminal Neuralgia - An Attractive Orphan Opportunity in the Pain Field', concludes that trigeminal neuralgia is an under-recognised indication, which possesses attractive commercial characteristics.
Historically, trigeminal neuralgia appears to have been discounted as a target indication, given its relatively small patient population combined with the entrenched position of carbamazepine as a highly effective front-line treatment. In contrast to these perceptions, this assessment identified trigeminal neuralgia to possess a number of appealing commercial features, and represents an interesting entry point into the broader pain market.
This report provides an in-depth assessment of the trigeminal neuralgia market based on detailed desk research as well as insight from 10 opinion-leading clinicians in the US and Europe. It assesses the gaps arising from the current management approaches, provides a view of the target product profile required for a novel pain therapy, scopes the peak sales potential, and identifies the key risks and commercialisation challenges. Overall, the report uncovers the scale of the opportunity in trigeminal neuralgia and the potential risks in this field.
About Globe Life Sciences and Globe Extraordinary
Globe Life Sciences provides commercial evaluation and information services within healthcare-related sectors.
Globe Life Sciences also provides off the shelf reports and databases to its healthcare clients under the Globe Extraordinary label. Globe Extraordinary reports are intended to assist managers in shaping and structuring their thinking in strategy development. Unlike our commercial evaluation service, these reports are designed for general - and often introductory - use.
For further information or to purchase this report, please contact sales: email@example.com
|Printer friendly Cite/link Email Feedback|
|Publication:||PR Newswire Europe|
|Date:||Jul 21, 2015|
|Previous Article:||SunEdison Acquires Mark Group, a Leading UK Energy Solutions Provider.|
|Next Article:||EU, Sahara Group to Partner on Improving Power and Child Nutrition in Nigeria.|